drugset / Trial / NCT04967664

Comparison of Qutenza (8% Capsaicin) With a Low-dose Capsaicin for Treatment of Nerve Pain After Surgery

NCT04967664

Phase 3 Completed 409 enrolled Averitas Pharma, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is an interventional, Phase III, double-blind, randomized, controlled, parallel-group, multi-site, clinical trial to confirm the efficacy and safety of repeated topical application of Qutenza (capsaicin 8% topical system) versus low-dose capsaicin control (capsaicin 0.04% topical system) in subjects with moderate to severe postsurgical neuropathic pain (PSNP).

Timeline

Start
2021-07-13
Primary completion
2025-08-28
Completion
2025-08-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Capsaicin Small molecule 0.04 % Topical
Subject Capsaicin Small molecule 8 % Topical

Indications